Dismiss Modal
Jamie Marie Aye, MD

Jamie Marie Aye, MD

Pediatric Hematology Oncology
Physician

Office Locations

Assistant Professor

Education

  • Residency: University of South Carolina, Palmetto Health
  • Medical School: Mercer University School of Medicine
  • Internship: University of South Carolina, Palmetto Health
  • UnderGraduate: Wake Forest University

Publications

1. Stafman, L. L., Williams, A. P., Garner, E. F., Aye, J. M., Stewart, J. E., Yoon, K. J., . . . Beierle, E. A. (2018). Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.. Transl Oncol, 12(2), 200-208. doi:10.1016/j.tranon.2018.10.008 2. Williams, A. P., Garner, E. F., Waters, A. M., Stafman, L. L., Aye, J. M., Markert, H., . . . Beierle, E. A. (2018). Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth.. Transl Oncol, 12(1), 84-95. doi:10.1016/j.tranon.2018.09.011 3. Garner, E. F., Stafman, L. L., Williams, A. P., Aye, J. M., Goolsby, C., Atigadda, V. R., . . . Beierle, E. A. (2018). UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.. J Neurooncol. doi:10.1007/s11060-018-2950-1 4. Stafman, L. L., Mruthyunjayappa, S., Waters, A. M., Garner, E. F., Aye, J. M., Stewart, J. E., . . . Beierle, E. A. (2018). Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.. Oncotarget, 9(32), 22665-22679. doi:10.18632/oncotarget.25205 5.Garner, E. F., Williams, A. P., Stafman, L. L., Aye, J. M., Mroczek-Musulman, E., Moore, B. P., . . . Beierle, E. A. (2018). FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.. Sci Rep, 8(1), 6913. doi:10.1038/s41598-018-25263-5